<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02503085</url>
  </required_header>
  <id_info>
    <org_study_id>NL1304</org_study_id>
    <secondary_id>2013-003366-14</secondary_id>
    <nct_id>NCT02503085</nct_id>
  </id_info>
  <brief_title>Ibuprofen Suspension Bioequivalence Study</brief_title>
  <official_title>A Randomized, Single-dose, 4-way Crossover, Open-label, Pharmacokinetic (PK) Study Comparing a 2% (w/v) Suspension of Ibuprofen (400 mg/20 mL Nurofen for Children®) With a Swiss Reference 2% (w/v) Suspension of Ibuprofen (400 mg/20 mL Algifor Dolo Junior®) in the Fed and Fasted States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reckitt Benckiser Healthcare (UK) Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reckitt Benckiser Healthcare (UK) Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the rate and extent of absorption of Ibuprofen
      suspension formulations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2, 2015</start_date>
  <completion_date type="Actual">August 25, 2015</completion_date>
  <primary_completion_date type="Actual">August 25, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Pre-dose, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480, 720 and 1440 mins (Day 1, Post-dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Administration to the Last Quantifiable Concentration at Time t (AUC0-t)</measure>
    <time_frame>Pre-dose, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480, 720 and 1440 mins (Day 1, Post-dose)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Elimination Rate Constant (Kel)</measure>
    <time_frame>Pre-dose, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480, 720 and 1440 mins (Day 1, Post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC From Administration to Infinity (AUC0-inf)</measure>
    <time_frame>Pre-dose, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480, 720 and 1440 mins (Day 1, Post-dose)</time_frame>
    <description>AUC0-inf = AUC0-t + (Ct/Kel), where Ct was the last quantifiable concentration at time t.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of AUC0-t/AUC0-inf (AUCR)</measure>
    <time_frame>Pre-dose, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480, 720 and 1440 mins (Day 1, Post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>Pre-dose, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480, 720 and 1440 mins (Day 1, Post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration Half-life (T1/2)</measure>
    <time_frame>Pre-dose, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480, 720 and 1440 mins (Day 1, Post-dose)</time_frame>
    <description>Terminal elimination half-life (T1/2) = ln(2)/Kel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration at Each Planned Nominal Time-point (Cn)</measure>
    <time_frame>Pre-dose, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480, 720 and 1440 mins (Day 1, Post-dose)</time_frame>
    <description>Cn was derived using linear interpolation from the 2 samples taken either side of the nominal time where there was a sampling time deviation. For concentrations that were missing due to blood samples not being taken Cn was not derived.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Adverse Events (AEs).</measure>
    <time_frame>Up to follow-up day 7</time_frame>
    <description>Intensity was determined by the Investigator. For symptomatic AEs the following definitions were applied.
Mild = AE did not limit usual activities; subject may have experienced slight discomfort.
Moderate = AE resulted in some limitation of usual activities; subject may have experienced significant discomfort.
Severe = AE resulted in an inability to carry out usual activities; subject may have experienced intolerable discomfort/pain.
Relationship to Investigational Medicinal Products (IMP)
Unassessable/Unclassified = Insufficient information to be able to make an assessment.
Conditional/ Unclassified = Insufficient information to make an assessment at present.
Unrelated = No possibility that AE was caused by IMP. Unlikely = Slight, but remote, chance that AE was caused by IMP. Possible = Reasonable suspicion that the AE was caused by IMP. Probable = Most likely that AE was caused by IMP. Certain = AE was definitely caused by IMP.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy Volunteer Study</condition>
  <arm_group>
    <arm_group_label>Nurofen for Children® (fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nurofen for Children® (fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Algifor Dolo Junior® (fasted)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Algifor Dolo Junior® (fed)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nurofen for Children®</intervention_name>
    <arm_group_label>Nurofen for Children® (fasted)</arm_group_label>
    <arm_group_label>Nurofen for Children® (fed)</arm_group_label>
    <other_name>Ibuprofen orange oral suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Algifor Dolo Junior®</intervention_name>
    <arm_group_label>Algifor Dolo Junior® (fasted)</arm_group_label>
    <arm_group_label>Algifor Dolo Junior® (fed)</arm_group_label>
    <other_name>Ibuprofen oral suspension</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have given written informed consent.

          -  Age: ≥18 years ≤50 years.

          -  Sex: Male or female subjects are eligible for entry.

          -  Female subject of child bearing potential with a negative pregnancy test at the
             screening visit and willing to use an effective method of contraception,

          -  Female subject of non-child bearing potential with negative pregnancy test at the
             screening visit

          -  Male subject willing to use an effective method of contraception, unless anatomically
             sterile

          -  Status: Healthy subjects as determined by past medical history, physical examination,
             vital signs, electrocardiogram, and laboratory tests at screening.

          -  Healthy Subjects with a Body Mass Index (BMI) of ≥20 and ≤27 kg/m2

        Exclusion Criteria:

          -  Pregnancy or lactating female subjects.

          -  A history of significant disease of any body system.

          -  Any condition that may currently interfere with the absorption, distribution,
             metabolism or excretion of drugs.

          -  A history of allergy or intolerance related to treatment with ibuprofen, aspirin or
             other Non-Steroidal Anti-inflammatory Drug,or the excipients of the formulations.

          -  A history of or active peptic or duodenal ulcers or gastro-intestinal bleed or upper
             gastro-intestinal bleed, or other significant gastro-intestinal disorders.

          -  A history of frequent dyspepsia, e.g. heartburn or indigestion.

          -  A history of migraine.

          -  Current smokers and ex-smokers who have smoked within 6 months.

          -  A history of drug abuse (including alcohol).

          -  High consumption of stimulating drinks (caffeine intake per day above 300 mg).

          -  Those with positive drugs of abuse screen including alcohol on any occasion throughout
             the study.

          -  Ingestion of a prescribed drug at any time in the 14 days before dosing with study
             medication (excluding hormonal contraceptives and hormone replacement therapy), or
             consumption of enzyme inhibitors or inducers during the previous month (such as
             barbiturates, carbamazepine, erythromycin, phenytoin, etc.).

          -  Ingestion of an over-the-counter preparation within 7 days before dosing with study
             medication.

          -  Donation of blood in quantity in the previous 12 weeks before enrolment into the
             study.

          -  Known human immune deficiency virus (HIV) positive status, or a positive viral
             serology screen.

          -  Topical use of ibuprofen within 7 days before dosing with study medication.

          -  Those previously randomised into this study.

          -  Employee at study site.

          -  Partner or first degree relative of the Investigator.

          -  Those who have participated in a clinical trial in the previous 12 weeks.

          -  Those unable in the opinion of the Investigator to comply fully with the study
             requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Reckit Benckiser</name>
      <address>
        <city>Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2015</study_first_submitted>
  <study_first_submitted_qc>July 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2015</study_first_posted>
  <results_first_submitted>August 31, 2017</results_first_submitted>
  <results_first_submitted_qc>April 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2018</results_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ibuprofen</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Total 60 subjects were screened and among them 16 subjects were screen failure, 2 subjects withdrew consent and 14 subjects were reserve.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1—BACD: Nurofen for Children® - Algifor Dolo Junior®</title>
          <description>B = Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition.
A = Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition.
C = Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition.
D = Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2—DCAB: Nurofen for Children® - Algifor Dolo Junior®</title>
          <description>D = Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition.
C = Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition.
A = Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition.
B = Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3—CBDA: Nurofen for Children® - Algifor Dolo Junior®</title>
          <description>C = Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition.
B = Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition.
D = Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition.
A = Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4—ADBC: Nurofen for Children® - Algifor Dolo Junior®</title>
          <description>A = Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition.
D = Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition.
B = Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition.
C = Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 1: Washout (3 to 7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2: Washout (3 to 7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3: Washout (3 to 7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted and fed conditions.
Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted and fed conditions.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.46" spread="8.660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.88" spread="10.909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.711" spread="0.1000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.07" spread="1.884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax)</title>
        <time_frame>Pre-dose, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480, 720 and 1440 mins (Day 1, Post-dose)</time_frame>
        <population>Analysis population included only subjects with evaluable plasma concentrations per treatment and who had taken at least one dose of medication in each treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: Nurofen for Children® 400 mg/20 mL (Fasted)</title>
            <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Treatment A: Nurofen for Children® 400 mg/20 mL (Fed)</title>
            <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: Algifor Dolo Junior® 400 mg/20 mL (Fasted)</title>
            <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
          </group>
          <group group_id="O4">
            <title>Treatment C: Algifor Dolo Junior® 400 mg/20 mL (Fed)</title>
            <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax)</title>
          <population>Analysis population included only subjects with evaluable plasma concentrations per treatment and who had taken at least one dose of medication in each treatment groups.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37499.938" spread="8983.3020"/>
                    <measurement group_id="O2" value="26207.273" spread="5788.1116"/>
                    <measurement group_id="O3" value="34752.646" spread="5205.5859"/>
                    <measurement group_id="O4" value="26377.382" spread="7496.1966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Administration to the Last Quantifiable Concentration at Time t (AUC0-t)</title>
        <time_frame>Pre-dose, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480, 720 and 1440 mins (Day 1, Post-dose)</time_frame>
        <population>Analysis population included only subjects with evaluable plasma concentrations per treatment and who had taken at least one dose of medication in each treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: Nurofen for Children® 400 mg/20 mL (Fasted)</title>
            <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Treatment A: Nurofen for Children® 400 mg/20 mL (Fed)</title>
            <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: Algifor Dolo Junior® 400 mg/20 mL (Fasted)</title>
            <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
          </group>
          <group group_id="O4">
            <title>Treatment C: Algifor Dolo Junior® 400 mg/20 mL (Fed)</title>
            <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Administration to the Last Quantifiable Concentration at Time t (AUC0-t)</title>
          <population>Analysis population included only subjects with evaluable plasma concentrations per treatment and who had taken at least one dose of medication in each treatment groups.</population>
          <units>min*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6139350.787" spread="1315534.5598"/>
                    <measurement group_id="O2" value="5783712.850" spread="1251017.0271"/>
                    <measurement group_id="O3" value="5912050.421" spread="1353655.3076"/>
                    <measurement group_id="O4" value="5639716.354" spread="1533625.9496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Rate Constant (Kel)</title>
        <time_frame>Pre-dose, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480, 720 and 1440 mins (Day 1, Post-dose)</time_frame>
        <population>Analysis population included only subjects with evaluable plasma concentrations per treatment and who had taken at least one dose of medication in each treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: Nurofen for Children® 400 mg/20 mL (Fasted)</title>
            <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Treatment A: Nurofen for Children® 400 mg/20 mL (Fed)</title>
            <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: Algifor Dolo Junior® 400 mg/20 mL (Fasted)</title>
            <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
          </group>
          <group group_id="O4">
            <title>Treatment C: Algifor Dolo Junior® 400 mg/20 mL (Fed)</title>
            <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Rate Constant (Kel)</title>
          <population>Analysis population included only subjects with evaluable plasma concentrations per treatment and who had taken at least one dose of medication in each treatment groups.</population>
          <units>1/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00599" spread="0.001238"/>
                    <measurement group_id="O2" value="0.00533" spread="0.001142"/>
                    <measurement group_id="O3" value="0.00602" spread="0.001221"/>
                    <measurement group_id="O4" value="0.00557" spread="0.001156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC From Administration to Infinity (AUC0-inf)</title>
        <description>AUC0-inf = AUC0-t + (Ct/Kel), where Ct was the last quantifiable concentration at time t.</description>
        <time_frame>Pre-dose, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480, 720 and 1440 mins (Day 1, Post-dose)</time_frame>
        <population>Analysis population included only subjects with evaluable plasma concentrations per treatment and who had taken at least one dose of medication in each treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: Nurofen for Children® 400 mg/20 mL (Fasted)</title>
            <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Treatment A: Nurofen for Children® 400 mg/20 mL (Fed)</title>
            <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: Algifor Dolo Junior® 400 mg/20 mL (Fasted)</title>
            <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
          </group>
          <group group_id="O4">
            <title>Treatment C: Algifor Dolo Junior® 400 mg/20 mL (Fed)</title>
            <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC From Administration to Infinity (AUC0-inf)</title>
          <description>AUC0-inf = AUC0-t + (Ct/Kel), where Ct was the last quantifiable concentration at time t.</description>
          <population>Analysis population included only subjects with evaluable plasma concentrations per treatment and who had taken at least one dose of medication in each treatment groups.</population>
          <units>min*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6215205.302" spread="1324821.9469"/>
                    <measurement group_id="O2" value="5927787.749" spread="1283566.5280"/>
                    <measurement group_id="O3" value="5986690.115" spread="1379614.0039"/>
                    <measurement group_id="O4" value="5733877.552" spread="1536788.1908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of AUC0-t/AUC0-inf (AUCR)</title>
        <time_frame>Pre-dose, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480, 720 and 1440 mins (Day 1, Post-dose)</time_frame>
        <population>Analysis population included only subjects with evaluable plasma concentrations per treatment and who had taken at least one dose of medication in each treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: Nurofen for Children® 400 mg/20 mL (Fasted)</title>
            <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Treatment A: Nurofen for Children® 400 mg/20 mL (Fed)</title>
            <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: Algifor Dolo Junior® 400 mg/20 mL (Fasted)</title>
            <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
          </group>
          <group group_id="O4">
            <title>Treatment C: Algifor Dolo Junior® 400 mg/20 mL (Fed)</title>
            <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of AUC0-t/AUC0-inf (AUCR)</title>
          <population>Analysis population included only subjects with evaluable plasma concentrations per treatment and who had taken at least one dose of medication in each treatment groups.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.988" spread="0.0059"/>
                    <measurement group_id="O2" value="0.976" spread="0.0184"/>
                    <measurement group_id="O3" value="0.988" spread="0.0074"/>
                    <measurement group_id="O4" value="0.983" spread="0.0118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cmax (Tmax)</title>
        <time_frame>Pre-dose, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480, 720 and 1440 mins (Day 1, Post-dose)</time_frame>
        <population>Analysis population included only subjects with evaluable plasma concentrations per treatment and who had taken at least one dose of medication in each treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: Nurofen for Children® 400 mg/20 mL (Fasted)</title>
            <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Treatment A: Nurofen for Children® 400 mg/20 mL (Fed)</title>
            <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: Algifor Dolo Junior® 400 mg/20 mL (Fasted)</title>
            <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
          </group>
          <group group_id="O4">
            <title>Treatment C: Algifor Dolo Junior® 400 mg/20 mL (Fed)</title>
            <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cmax (Tmax)</title>
          <population>Analysis population included only subjects with evaluable plasma concentrations per treatment and who had taken at least one dose of medication in each treatment groups.</population>
          <units>min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4" spread="17.33"/>
                    <measurement group_id="O2" value="72.0" spread="33.70"/>
                    <measurement group_id="O3" value="52.3" spread="40.91"/>
                    <measurement group_id="O4" value="71.7" spread="48.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration Half-life (T1/2)</title>
        <description>Terminal elimination half-life (T1/2) = ln(2)/Kel</description>
        <time_frame>Pre-dose, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480, 720 and 1440 mins (Day 1, Post-dose)</time_frame>
        <population>Analysis population included only subjects with evaluable plasma concentrations per treatment and who had taken at least one dose of medication in each treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: Nurofen for Children® 400 mg/20 mL (Fasted)</title>
            <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Treatment A: Nurofen for Children® 400 mg/20 mL (Fed)</title>
            <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: Algifor Dolo Junior® 400 mg/20 mL (Fasted)</title>
            <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
          </group>
          <group group_id="O4">
            <title>Treatment C: Algifor Dolo Junior® 400 mg/20 mL (Fed)</title>
            <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration Half-life (T1/2)</title>
          <description>Terminal elimination half-life (T1/2) = ln(2)/Kel</description>
          <population>Analysis population included only subjects with evaluable plasma concentrations per treatment and who had taken at least one dose of medication in each treatment groups.</population>
          <units>min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.122" spread="28.6677"/>
                    <measurement group_id="O2" value="137.555" spread="37.6325"/>
                    <measurement group_id="O3" value="120.879" spread="30.5194"/>
                    <measurement group_id="O4" value="130.460" spread="30.7138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration at Each Planned Nominal Time-point (Cn)</title>
        <description>Cn was derived using linear interpolation from the 2 samples taken either side of the nominal time where there was a sampling time deviation. For concentrations that were missing due to blood samples not being taken Cn was not derived.</description>
        <time_frame>Pre-dose, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 180, 240, 360, 480, 720 and 1440 mins (Day 1, Post-dose)</time_frame>
        <population>Analysis population included only subjects with evaluable plasma concentrations per treatment and who had taken at least one dose of medication in each treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: Nurofen for Children® 400 mg/20 mL (Fasted)</title>
            <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Treatment A: Nurofen for Children® 400 mg/20 mL (Fed)</title>
            <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: Algifor Dolo Junior® 400 mg/20 mL (Fasted)</title>
            <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
          </group>
          <group group_id="O4">
            <title>Treatment C: Algifor Dolo Junior® 400 mg/20 mL (Fed)</title>
            <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration at Each Planned Nominal Time-point (Cn)</title>
          <description>Cn was derived using linear interpolation from the 2 samples taken either side of the nominal time where there was a sampling time deviation. For concentrations that were missing due to blood samples not being taken Cn was not derived.</description>
          <population>Analysis population included only subjects with evaluable plasma concentrations per treatment and who had taken at least one dose of medication in each treatment groups.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time Post-Dose - 10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5934.077" spread="6885.8643"/>
                    <measurement group_id="O2" value="5473.173" spread="7955.4756"/>
                    <measurement group_id="O3" value="5579.436" spread="5074.7709"/>
                    <measurement group_id="O4" value="4647.090" spread="6289.5788"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Post-Dose - 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12315.358" spread="10819.4956"/>
                    <measurement group_id="O2" value="8486.946" spread="9318.9385"/>
                    <measurement group_id="O3" value="12251.837" spread="9535.7628"/>
                    <measurement group_id="O4" value="8566.950" spread="8227.2989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Post-Dose - 20 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18776.528" spread="13893.1674"/>
                    <measurement group_id="O2" value="11491.148" spread="10579.5320"/>
                    <measurement group_id="O3" value="18346.910" spread="12216.1356"/>
                    <measurement group_id="O4" value="11489.917" spread="8402.4627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Post-Dose - 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27860.671" spread="12228.9507"/>
                    <measurement group_id="O2" value="16171.896" spread="10459.1021"/>
                    <measurement group_id="O3" value="27557.463" spread="10049.7928"/>
                    <measurement group_id="O4" value="17619.547" spread="10451.6496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Post-Dose - 40 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31484.356" spread="7963.3886"/>
                    <measurement group_id="O2" value="20109.864" spread="9451.0500"/>
                    <measurement group_id="O3" value="31258.579" spread="7630.5525"/>
                    <measurement group_id="O4" value="21794.588" spread="10810.9958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Post-Dose - 50 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32538.663" spread="9976.7494"/>
                    <measurement group_id="O2" value="22216.449" spread="8667.4972"/>
                    <measurement group_id="O3" value="31026.608" spread="6935.4647"/>
                    <measurement group_id="O4" value="23041.910" spread="10063.5154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Post-Dose - 60 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30424.660" spread="5407.6867"/>
                    <measurement group_id="O2" value="22645.898" spread="7482.6836"/>
                    <measurement group_id="O3" value="28751.529" spread="6440.3355"/>
                    <measurement group_id="O4" value="22226.638" spread="7893.6789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Post-Dose - 70 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28817.725" spread="4189.7125"/>
                    <measurement group_id="O2" value="22585.564" spread="6387.2660"/>
                    <measurement group_id="O3" value="26979.890" spread="6495.2967"/>
                    <measurement group_id="O4" value="21619.517" spread="6805.8715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Post-Dose - 80 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27236.542" spread="4944.7693"/>
                    <measurement group_id="O2" value="21532.327" spread="5367.9576"/>
                    <measurement group_id="O3" value="25528.950" spread="6286.8439"/>
                    <measurement group_id="O4" value="21132.032" spread="6103.8828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Post-Dose - 90 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26045.659" spread="4445.1832"/>
                    <measurement group_id="O2" value="20697.612" spread="4961.1992"/>
                    <measurement group_id="O3" value="24080.631" spread="6464.0707"/>
                    <measurement group_id="O4" value="20182.637" spread="5379.6131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Post-Dose - 105 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23391.182" spread="4298.8943"/>
                    <measurement group_id="O2" value="19525.222" spread="3347.9779"/>
                    <measurement group_id="O3" value="22336.377" spread="5049.6930"/>
                    <measurement group_id="O4" value="18500.837" spread="4736.1272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Post-Dose - 120 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20702.122" spread="4461.6587"/>
                    <measurement group_id="O2" value="18414.660" spread="3038.3137"/>
                    <measurement group_id="O3" value="20053.854" spread="4561.3611"/>
                    <measurement group_id="O4" value="17112.477" spread="4579.0063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Post-Dose - 180 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14091.791" spread="3856.4139"/>
                    <measurement group_id="O2" value="13597.701" spread="3653.1273"/>
                    <measurement group_id="O3" value="13062.561" spread="3345.8475"/>
                    <measurement group_id="O4" value="12893.527" spread="3436.8623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Post-Dose - 240 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9649.611" spread="2767.9584"/>
                    <measurement group_id="O2" value="10997.109" spread="3518.9434"/>
                    <measurement group_id="O3" value="9483.481" spread="3427.9947"/>
                    <measurement group_id="O4" value="9895.761" spread="3586.4589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Post-Dose - 360 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3992.230" spread="1611.5462"/>
                    <measurement group_id="O2" value="5390.090" spread="2071.2073"/>
                    <measurement group_id="O3" value="3830.211" spread="1667.1184"/>
                    <measurement group_id="O4" value="5612.610" spread="4105.1920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Post-Dose - 480 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1942.286" spread="948.4031"/>
                    <measurement group_id="O2" value="2839.215" spread="1352.4747"/>
                    <measurement group_id="O3" value="1930.929" spread="1069.7491"/>
                    <measurement group_id="O4" value="2650.093" spread="1697.3457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Post-Dose - 720 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="560.199" spread="343.2360"/>
                    <measurement group_id="O2" value="829.589" spread="460.9511"/>
                    <measurement group_id="O3" value="544.660" spread="417.5077"/>
                    <measurement group_id="O4" value="788.223" spread="646.7288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time Post-Dose - 1440 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.547" spread="34.2600"/>
                    <measurement group_id="O2" value="149.707" spread="36.4129"/>
                    <measurement group_id="O3" value="189.103" spread="85.3662"/>
                    <measurement group_id="O4" value="145.298" spread="15.3467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Adverse Events (AEs).</title>
        <description>Intensity was determined by the Investigator. For symptomatic AEs the following definitions were applied.
Mild = AE did not limit usual activities; subject may have experienced slight discomfort.
Moderate = AE resulted in some limitation of usual activities; subject may have experienced significant discomfort.
Severe = AE resulted in an inability to carry out usual activities; subject may have experienced intolerable discomfort/pain.
Relationship to Investigational Medicinal Products (IMP)
Unassessable/Unclassified = Insufficient information to be able to make an assessment.
Conditional/ Unclassified = Insufficient information to make an assessment at present.
Unrelated = No possibility that AE was caused by IMP. Unlikely = Slight, but remote, chance that AE was caused by IMP. Possible = Reasonable suspicion that the AE was caused by IMP. Probable = Most likely that AE was caused by IMP. Certain = AE was definitely caused by IMP.</description>
        <time_frame>Up to follow-up day 7</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: Nurofen for Children® 400 mg/20 mL (Fasted)</title>
            <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
          </group>
          <group group_id="O2">
            <title>Treatment A: Nurofen for Children® 400 mg/20 mL (Fed)</title>
            <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
          </group>
          <group group_id="O3">
            <title>Treatment D: Algifor Dolo Junior® 400 mg/20 mL (Fasted)</title>
            <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition.</description>
          </group>
          <group group_id="O4">
            <title>Treatment C: Algifor Dolo Junior® 400 mg/20 mL (Fed)</title>
            <description>Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events (AEs).</title>
          <description>Intensity was determined by the Investigator. For symptomatic AEs the following definitions were applied.
Mild = AE did not limit usual activities; subject may have experienced slight discomfort.
Moderate = AE resulted in some limitation of usual activities; subject may have experienced significant discomfort.
Severe = AE resulted in an inability to carry out usual activities; subject may have experienced intolerable discomfort/pain.
Relationship to Investigational Medicinal Products (IMP)
Unassessable/Unclassified = Insufficient information to be able to make an assessment.
Conditional/ Unclassified = Insufficient information to make an assessment at present.
Unrelated = No possibility that AE was caused by IMP. Unlikely = Slight, but remote, chance that AE was caused by IMP. Possible = Reasonable suspicion that the AE was caused by IMP. Probable = Most likely that AE was caused by IMP. Certain = AE was definitely caused by IMP.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Emergent Adverse Event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity - Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity - Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity - Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP - Certain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP - Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP - Possible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP - Unlikely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP - Unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP – Conditional/Unclassified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relationship to IMP – Unassessable /Unclassifiable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to follow-up day 7</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Overall Study</title>
          <description>Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted and fed conditions.
Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted and fed conditions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Director</name_or_title>
      <organization>Reckitt Benckiser Healthcare (UK) Ltd.</organization>
      <phone>+441482 326151</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

